

Hit optimization and lead generation activating PROKR1 to prevent and treat sarcopenia

Seoul National University



METABOLIC	Hit
Product Type	Small molecule
Indication	Sarcopenia, sarcopenic obesity
Target	Prokineticin receptor 1 (PROKR1/GPR73)
MOA(Mechanism of Action)	<ul style="list-style-type: none"> ① PROKR1 agonist ② Activation of PROKR1-CREB-NR4A2 to increase muscle mass, strength, and basal metabolic rate
Competitiveness	<ul style="list-style-type: none"> ① A novel therapeutic target and mechanism differentiated from androgens and myostatin, which have failed to demonstrate clinical efficacy ② Unlike BYM338 (Bimagrumab, Versanis/Eli Lilly), which is a myostatin-neutralizing antibody that inhibits muscle catabolism, it is a small molecule that can be administered orally
Development Stage	Hit
Route of Administration	Oral